Trial Profile
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Octreotide
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 15 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 31 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
- 04 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.